Effects of 25-Hydroxyvitamin D3 on Proliferation and Osteoblast Differentiation of Human Marrow Stromal Cells Require CYP27B1/1α-Hydroxylase

被引:64
|
作者
Geng, Shuo [1 ,2 ]
Zhou, Shuanhu [1 ]
Glowacki, Julie [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Dept Orthoped Surg, Sch Med, Boston, MA 02115 USA
[2] Harbin Med Univ, Dept Orthoped Surg, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China
关键词
BONE MARROW STROMAL CELLS; VITAMIN D; PROLIFERATION; OSTEOBLAST DIFFERENTIATION; APOPTOSIS; VITAMIN-D; 1,25-DIHYDROXYVITAMIN D-3; OSTEOGENIC DIFFERENTIATION; STEM-CELLS; BONE; GROWTH; APOPTOSIS; EXPRESSION; 1,25(OH)(2)D-3; RECEPTOR;
D O I
10.1002/jbmr.298
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1,25-Dihydroxyvitamin D-3 [1,25(OH)(2)D-3] has many noncalcemic actions that rest on inhibition of proliferation and promotion of differentiation in malignant and normal cell types. 1,25(OH)(2)D-3 stimulates osteoblast differentiation of human marrow stromal cells (hMSCs), but little is known about the effects of 25-hydroxyvitamin D-3 [25(OH)D-3] on these cells. Recent evidence shows that hMSCs participate in vitamin D metabolism and can activate 25(OH)D-3 by CYP27B1/1 alpha-hydroxylase. These studies test the hypothesis that antiproliferative and prodifferentiation effects of 25(OH) D3 in hMSCs depend on CYP27B1. We studied hMSCs that constitutively express high (hMSCs(hi-1 alpha)) or low (hMSCs(lo-1 alpha)) levels of CYP27B1 with equivalent expression of CYP24A1 and vitamin D receptor. In hMSCs(hi-1 alpha), 25(OH)D-3 reduced proliferation, downregulated proliferating cell nuclear antigen (PCNA), upregulated p21(Waf1/Cip1), and decreased cyclin D1. Unlike 1,25(OH)(2)D-3, the antiapoptotic effects of 25(OH)D-3 on Bax and Bcl-2 were blocked by the P450 inhibitor ketoconazole. The antiproliferative effects of 25(OH)D-3 in hMSCs(hi-1 alpha) and of 1,25(OH)(2)D-3 in both samples of hMSCs were explained by cell cycle arrest, not by increased apoptosis. Stimulation of osteoblast differentiation in hMSCs(hi-1 alpha) by 25(OH)D-3 was prevented by ketoconazole and upon transfection with CYP27B1 siRNA. These data indicate that CYP27B1 is required for 25(OH)D-3's action in hMSCs. Three lines of evidence indicate that CYP27B1 is required for the antiproliferative and prodifferentiation effects of 25(OH)D-3 on hMSCs: Those effects were not seen (1) in hMSCs with low constitutive expression of CYP27B1, (2) in hMSCs treated with ketoconazole, and (3) in hMSCs in which CYP27B1 expression was silenced. Osteoblast differentiation and skeletal homeostasis may be regulated by autocrine/paracrine actions of 25(OH)D-3 in hMSCs. (C) 2011 American Society for Bone and Mineral Research.
引用
收藏
页码:1145 / 1153
页数:9
相关论文
共 50 条
  • [1] 25-hydroxyvitamin D3-1a-hydroxylase (CYP27B1) splice variants in human skin
    Seifert, Markus
    Tilgen, Wolfgang
    Reichrath, Joerg
    [J]. ANTICANCER RESEARCH, 2008, 28 (3A) : 1623 - 1623
  • [2] Metabolism of substrates incorporated into phospholipid vesicles by mouse 25-hydroxyvitamin D3 1α-hydroxylase (CYP27B1)
    Tang, Edith K. Y.
    Voo, Kimberley J. Q.
    Nguyen, Minh N.
    Tuckey, Robert C.
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 119 (3-5): : 171 - 179
  • [3] 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1) induces ectopic calcification
    Yimamu, Yilimulati
    Ohtani, Ayako
    Takei, Yuichiro
    Furuichi, Airi
    Kamei, Yuki
    Yamanaka-Okumura, Hisami
    Ohminami, Hirokazu
    Masuda, Masashi
    Miyazaki, Makoto
    Yamamoto, Hironori
    Taketani, Yutaka
    [J]. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2022, 71 (02) : 103 - 111
  • [4] Sequence variants in the human 25-hydroxyvitamin D3 1-α-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk
    Hawkins, GA
    Cramer, SD
    Zheng, SL
    Isaacs, SD
    Wiley, KE
    Chang, BL
    Bleecker, ER
    Walsh, PC
    Meyers, DA
    Isaacs, WB
    Xu, JF
    [J]. PROSTATE, 2002, 53 (03): : 175 - 178
  • [5] Effects of 1,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 on osteoblast differentiation in human marrow stromal cell cultures.
    Glowacki, J
    Mueller, SM
    Greenberger, JS
    Bleiberg, I
    LeBoff, MS
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S351 - S351
  • [6] Homology modeling of human 25-hydroxyvitamin D3 1α-hydroxylase (CYP27B1) based on the crystal structure of rabbit CYP2C5
    Yamamoto, K
    Masuno, H
    Sawada, N
    Sakaki, T
    Inouye, K
    Ishiguro, M
    Yamada, S
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5): : 167 - 171
  • [7] Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells
    Karlsson, Sandra
    Diaz Cruz, Maria Araceli
    Faresjo, Maria
    Khamou, Athanasia Papadopoulou
    Larsson, Dennis
    [J]. ANTICANCER RESEARCH, 2021, 41 (10) : 4733 - 4740
  • [8] Conventional and tissue-specific inactivation of the 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1)
    St-Arnaud, R
    Dardenne, O
    Prud'homme, J
    Hacking, SA
    Glorieux, FH
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) : 245 - 251
  • [9] Prediction of Osteoporotic Fracture Risk by 25-hydroxyvitamin D3-1α-hydroxylase (CYP27B1) Gene.
    Tran, B. H.
    Au, A.
    Nguyen, N. D.
    Clifton-Bligh, R.
    Center, J. R.
    Eisman, J. A.
    Nguyen, T. V.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S438 - S438
  • [10] Gene amplification and splice variants of 25-hydroxyvitamin D3 1,α-hydroxylase (CYP27B1) in glioblastoma multiforme -: A possible role in tumor progression?
    Diesel, B
    Fischer, U
    Meese, E
    [J]. VITAMIN D ANALOGS IN CANCER PREVENTION AND THERAPY, 2003, 164 : 151 - 155